Differences in proteoglycan deposition in the airways of moderate and severe asthmatics

Meakins-Christie Laboratories, Montreal Chest Institute, McGill University Hospital Centre, Université de Montréal, Montreal, QC, Canada.
European Respiratory Journal (Impact Factor: 7.13). 02/2007; 29(1):71-7. DOI: 10.1183/09031936.00047905
Source: PubMed

ABSTRACT Excess deposition of proteoglycans (PGs) has been described in the subepithelial layer of the asthmatic airway wall. However, less is known about deposition in the airway smooth muscle (ASM) layer, and whether the pattern of deposition is altered depending upon disease severity. Endobronchial biopsies were performed in patients with severe or moderate asthma (defined using American Thoracic Society criteria) and in control subjects. Biopsies were immunostained for the PGs biglycan, lumican, versican and decorin. PG deposition was measured in the subepithelial and ASM layers, the former by calculating the area of positive staining, and the latter by determining the percentage area stained using point counting. Immunostaining for PGs was prominent in biopsies from both moderate and severe asthmatics, compared with control subjects. While there was no difference in the amount of PG in the subepithelial layer between the two asthmatic groups, the percentage area of biglycan and lumican staining in the ASM layer was significantly greater in moderate versus severe asthmatics. Differences in the deposition of proteoglycans within the airway smooth muscle layer of moderate versus severe asthmatics potentially impact on the functional behaviour of the airway smooth muscle in these two groups of patients.

Download full-text


Available from: Laura Pini, Aug 01, 2015
  • Source
    • "A recent study has demonstrated, in vivo, in an animal model, that methacholine responsiveness and the effect of changing lung volume on mechanics are altered when ECM is genetically altered [5]. Finally, differences in the ECM deposition within the airway smooth muscle layer of moderate versus severe asthmatics have been demonstrated , with a potential impact on airway smooth muscle behavior [6]. The ASM cell is emerging as a key cell in airway remodeling of asthma [7] [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Airway remodeling is a main feature of asthma. Different biological phenotypes of severe asthma have been recently recognized by the ENFUMOSA study group and among these one is characterized by neutrophilic airway inflammation. Concentrations of MMP-9 in airways have been suggested as a marker to monitor airway remodeling in asthma. The aim of the present study was to explore airway remodeling in different biological phenotypes of asthma by measuring MMP-9 in EBC and correlating these with other variables. Sixty consecutive subjects with asthma and 20 healthy controls were enrolled in the study. Exhaled MMP-9, pH and NO levels and inflammatory cells in sputum were measured in all subjects enrolled. We observed an increase of exhaled MMP-9 in asthmatic subjects compared to controls. Higher exhaled MMP-9 concentrations were described in severe asthmatics compared to mild to moderate especially in those with neutrophilic airway inflammation. We further found a correlation between exhaled MMP-9 and percentage of neutrophils in sputum, FEV1, exhaled NO and pH. Our results seem to substantiate the feasibility of measuring exhaled MMP-9 in the breath of asthmatic patients. MMP-9 may be considered a proxy of the amount of the ongoing airway remodeling in asthma. MMP-9 has been shown to be differentially released in different phenotypes of asthma. The measure of exhaled MMP-9 could help to monitor the ongoing airway remodeling, recognize severe stages of asthma, and possibly help determine the appropriate choice of therapy.
    European Journal of Internal Medicine 09/2013; DOI:10.1016/j.ejim.2013.08.705 · 2.30 Impact Factor
  • Source
    • "Perhaps the most important feature of asthmatic airway remodeling is thickening of the airway smooth muscle layer (James and Carroll, 2000; James et al., 2012). This includes hypertrophy and hyperplasia of the muscle cells, as well as altered deposition of extracellular matrix (Woodruff et al., 2004; Begueret et al., 2007; Pini et al., 2007; Hassan et al., 2010). Increased smooth muscle mass is highly likely to contribute to AHR because thickening of the airway wall may decrease the degree of airway smooth muscle shortening required to occlude the lumen (James et al., 1989; James and Wenzel, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Whether mouse models of chronic asthma can be used to investigate the relationship between airway inflammation/remodeling and airway hyper-responsiveness (AHR) is a vexed question. It raises issues about the extent to which such models replicate key features of the human disease. Here, we review some of the characteristic pathological features of human asthma and their relationship to AHR and examine some limitations of mouse models that are commonly used to investigate these relationships. We compare these conventional models with our mouse model of chronic asthma involving long-term low-level inhalational challenge and review studies of the relationship between inflammation/remodeling and AHR in this model and its derivatives, including models of an acute exacerbation of chronic asthma and of the induction phase of childhood asthma. We conclude that while extrapolating from studies in mouse models to AHR in humans requires cautious interpretation, such experimental work can provide significant insights into the pathogenesis of airway responsiveness and its molecular and cellular regulation.
    Frontiers in Physiology 07/2012; 3:312. DOI:10.3389/fphys.2012.00312 · 3.50 Impact Factor
  • Source
    • "Asthma Mouse, rat, human Pini et al. 2007; Pinelli et al. 2009; Nihlberg et al. 2010; Venkatesan et al. 2012 Atherosclerosis Mouse, rat, human Skalen et al. 2002; Nakashima et al. 2007 Cancer Human Mintz et al. 2005; Coulson-Thomas et al. 2011; Gu et al. 2012; Wang B et al. 2011 Diabetes Mouse, rat, human Schaefer et al. 2001; Thompson et al. 2011; Bolton et al. 2012 Duchenne muscular dystrophy Mouse, human Fadic et al. 2006; Mercado et al. 2006; Brandan et al. 2008; Amenta et al. 2011 Intervertebral disc disorders Human Brown et al. 2012 Fibrotic liver disease Rat, human Meyer et al. 1992; Krull et al. 1993; Gressner 1994; Hogemann et al. 1997 Myocardial infarction Mouse, human Campbell et al. 2008; Westermann et al. 2008 Multiple sclerosis Human Mohan et al. 2010 Osteoarthritis Mouse Wadhwa et al. 2005; Embree et al. 2010 Osteoporosis Mouse Xu et al. 1998 Perimyocarditis Mouse Popovic et al. 2011 Fibrotic kidney disease Mouse, rat, human Schaefer et al. 1998; Schaefer et al. 2000; Kuroda et al. 2004; Schaefer 2011 Rheumatic arthritis Human Polgar et al. 2003; Sokolove et al. 2012; Antipova and Orgel 2012 Sepsis Mouse Schaefer et al. 2005; Babelova et al. 2009 Systemic lupus erythematosus Mouse, human Moreth et al. 2010 Recent data provide evidence for a crucial role of biglycan in the regulation of inflammation, bone growth, and muscle development and regeneration. This brief review aims to focus on the mechanisms and consequences of biglycan interaction with cell surface molecules/receptors in those processes to underline the role of biglycan as a multivalent , matrix-derived signaling molecule. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research over the past few years has provided fascinating results indicating that biglycan, besides being a ubiquitous structural component of the extracellular matrix (ECM), may act as a signaling molecule. Proteolytically released from the ECM, biglycan acts as a danger signal signifying tissue stress or injury. As a ligand of innate immunity receptors and activator of the inflammasome, biglycan stimulates multifunctional proinflammatory signaling linking the innate to the adaptive immune response. By clustering several types of receptors on the cell surface and orchestrating their downstream signaling events, biglycan is capable to autonomously trigger sterile inflammation and to potentiate the inflammatory response to microbial invasion. Besides operating in a broad biological context, biglycan also displays tissue-specific affinities to certain receptors and structural components, thereby playing a crucial role in bone formation, muscle integrity, and synapse stability at the neuromuscular junction. This review attempts to provide a concise summary of recent data regarding the involvement of biglycan in the regulation of inflammation and the musculoskeletal system, pointing out both a signaling and a structural role for this proteoglycan. The potential of biglycan as a novel therapeutic target or agent for the treatment of inflammatory diseases and skeletal muscular dystrophies is also addressed.
    Journal of Histochemistry and Cytochemistry 07/2012; 60(12). DOI:10.1369/0022155412456380 · 2.40 Impact Factor
Show more